공시 • Mar 31
WOOJUNG BIO, Inc. announced that it has received KRW 35 billion in funding from Kolmar Holdings Co.,Ltd. On March 30, 2026, WOOJUNG BIO, Inc. closed the transaction. 공시 • Mar 17
WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026 WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea 공시 • Mar 04
WOOJUNG BIO, Inc. announced that it expects to receive KRW 35 billion in funding from Kolmar Holdings Co.,Ltd. WOOJUNG BIO, Inc. announced a private placement of 9th Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 35,000,000,000 on March 3, 2026. The transaction includes investor participation of Kolmar Holdings Co.,Ltd. for bonds. The Bonds are 100% convertible into 15,053,763 common shares of the company at a conversion price value of KRW 2,325 and carry interest rate of 0% and maturity interest rate of 4%. The conversion billing period starts from March 31, 2027 to February 28, 2030.The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of March 3, 2030. The transaction is expected to close on March 30, 2026. The transaction is subject to 1 year hold period. New Risk • Mar 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩51.0b market cap, or US$34.5m). New Risk • Aug 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩3.4b free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩27.9b market cap, or US$20.1m). New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩31.7b market cap, or US$23.0m). New Risk • Mar 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 204% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩24.9b market cap, or US$17.0m). 공시 • Mar 14
WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025 WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩27.3b market cap, or US$19.0m). Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩1,719, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 75% over the past three years. 공시 • Nov 20
WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.0425 billion in funding from Shin Nippon Biomedical Laboratories, Ltd. WOOJUNG BIO, Inc. announced private placement of 950,000 common shares at a price of KRW 2,150 for gross proceeds of KRW 2,042,500,000 on November 20, 2024. The transaction includes participation from Shin Nippon Biomedical Laboratories, Ltd. The transaction has been approved by the board of directors of the company. The payment date of the transaction is December 5, 2024. The offering is subject to mandatory lockup for 1 year. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to ₩1,917, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 14x in the Life Sciences industry in South Korea. Total loss to shareholders of 70% over the past three years. Valuation Update With 7 Day Price Move • Aug 27
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to ₩2,690, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 15x in the Life Sciences industry in South Korea. Total loss to shareholders of 60% over the past three years. New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩248m free cash flow). Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (₩20.7b market cap, or US$15.0m). New Risk • Feb 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.9b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (₩26.2b market cap, or US$19.7m). New Risk • Sep 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩9.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩9.0b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$24.0m). New Risk • Jul 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩36.7b market cap, or US$29.0m). 공시 • Jun 01
WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd. On May 31, 2023, WOOJUNG BIO, Inc. closed the transaction. 공시 • May 27
WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd. WOOJUNG BIO, Inc. announced a private placement of series 8th unregistered private convertible bond for gross proceeds of KRW 5,000,000,000 on May 25, 2023. The transaction will involve participation from new investor Korea Investment Re-Up II Fund, a fund managed by Korea Investment Partners Co. Ltd. The transaction has been approved by the board of directors. The bonds to be issued will have a hold period of one year, post the closing. The bond will mature on May 31, 2027. The bonds will have surface interest rate of 0% and interest rate of maturity rate of 4%. The bonds are fully convertible at a price of KRW 3,143 per share into1,590,836 shares into 10.93% stake. The bonds conversion period starts from May 31, 2024 and ends on April 30, 2027. The transaction is expected to close on May 31, 2023. 공시 • May 26
WOOJUNG BIO, Inc. announced that it has received KRW 8.999979915 billion in funding from Mercury Asset Management Co., Ltd., Ryan Asset Management Co., Ltd., Timefolio Asset Management Co.,Ltd On May 25, 2022, WOOJUNG BIO, Inc. closed the transaction. 공시 • Aug 28
WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding On August 27, 2021, WOOJUNG BIO, Inc. (KOSDAQ:A215380) closed the transaction. Is New 90 Day High Low • Feb 18
New 90-day low: ₩7,110 The company is down 41% from its price of ₩12,100 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩7,400 The company is down 3.0% from its price of ₩7,620 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period. Valuation Update With 7 Day Price Move • Dec 01
Market bids up stock over the past week After last week's 20% share price gain to ₩13,100, the stock is trading at a trailing P/E ratio of 50x, up from the previous P/E ratio of 41.6x. This compares to an average P/E of 80x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 161%. Is New 90 Day High Low • Dec 01
New 90-day high: ₩13,100 The company is up 8.0% from its price of ₩12,150 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 2.0% over the same period. Valuation Update With 7 Day Price Move • Nov 19
Market bids up stock over the past week After last week's 51% share price gain to ₩11,600, the stock is trading at a trailing P/E ratio of 44.3x, up from the previous P/E ratio of 29.3x. This compares to an average P/E of 78x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 116%. Valuation Update With 7 Day Price Move • Nov 16
Market bids up stock over the past week After last week's 17% share price gain to ₩9,610, the stock is trading at a trailing P/E ratio of 36.7x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 77x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 93%. Is New 90 Day High Low • Oct 26
New 90-day low: ₩7,590 The company is down 10.0% from its price of ₩8,390 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period. 공시 • Sep 19
Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion. Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion on August 28, 2020. Chun Byung Nyun acquired 772,831 shares at KRW 5,661 per share by exercise of call option rights.
Chun Byung Nyun completed the acquisition of an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on August 28, 2020. 공시 • Jul 31
ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion. ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion on July 22, 2020. Under the terms, ByungNyun acquired 353,294 shares of WOOJUNG at KRW 5,661 per share. On completion, ByungNyun holds 41.75% stake in WOOJUNG. ByungNyun Chun is financing this transaction by borrowing funds from HYUNDAI MOTOR SECURITIES CO.,LTD. and Hana Bank
ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., completed the acquisition of an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on July 22, 2020. 
